EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A Spike-Linked HPV16 E7 DNA Vaccine Induces Potent Antitumor and Anti-Spike Immune Responses

Yichu Xu iD, Yining Liu, Yu-Cheng Chang, Ya-Chea Tsai, Chuan-Hsiang Huang iD, Tzyy-Choou Wu, Chien-Fu Hung

International Journal of Molecular Sciences · 14.07.2026 · 27 (14) · 6249

DOI: 10.3390/ijms27146249 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 14.07.2026. Verfasst von Yichu Xu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Johns Hopkins University School of Medicine, 1550 Orleans Street, CRB II 307, Baltimore, MD 21287, USA. Hauptthemen laut MEDLINE: Papillomavirus E7 Proteins, Vaccines, DNA, Spike Glycoprotein, Coronavirus, Human papillomavirus 16. Die Arbeit nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIH/NCI Specialized Program of Research Excellence (SPORE) in Cervical Cancer, NIDCR NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Persistent infection with high-risk human papillomavirus (HPV), particularly HPV16, is a major driver of HPV-associated cancers; however, strategies for treating established HPV-induced tumors remain scarce. Here, we developed a DNA-based vaccine linking the SARS-CoV-2 spike (S) protein with an HPV16 E7 epitope (aa 49-57) to simultaneously induce antiviral humoral immunity and antitumor cellular responses. We generated 2 constructs, S-E7 and S-RE7, with the latter incorporating a furin cleavage site (R) to enhance antigen processing. In vitro, S-RE7 significantly enhanced E7-specific CD8+ T cell activation compared to S-E7, highlighting the importance of the furin sequence. In vivo, both S-linked vaccines elicited robust E7-specific CD8+ T cell responses and provided complete protection against TC-1 tumor challenge in a prophylactic murine model, with long-lasting immunity upon tumor rechallenge. In therapeutic settings, vaccination with S-E7 or S-RE7 significantly suppressed tumor growth, extended survival, and reduced circulating myeloid-derived suppressor cells (MDSCs), indicating alleviation of systemic immunosuppression. Notably, S-RE7 demonstrated faster antitumor effects overall in early tumor progression. In addition to cellular immunity, both constructs induced high levels of anti-spike antibodies, with S-RE7 eliciting approximately fourfold higher responses than S-E7. Furthermore, S-RE7 effectively boosted pre-existing anti-spike immunity in mice that were previously vaccinated. This “two-in-one” strategy represents a promising and versatile platform for the prevention and treatment of HPV-associated cancers while maintaining preparedness against potential SARS-CoV-2.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Papillomavirus E7 ProteinsVaccines, DNASpike Glycoprotein, CoronavirusHuman papillomavirus 16Cancer VaccinesPapillomavirus VaccinesAnimalsMiceFemaleCD8-Positive T-LymphocytesHumansSARS-CoV-2Papillomavirus InfectionsMice, Inbred C57BLCOVID-19Immunity, Cellular

Stichwörter der Autor:innen

DNA vaccinecancerimmunotherapyspike protein

Substanzen

Papillomavirus E7 ProteinsVaccines, DNASpike Glycoprotein, Coronavirusoncogene protein E7, Human papillomavirus type 16spike protein, SARS-CoV-2Cancer VaccinesPapillomavirus Vaccines

Autor:innen und Institutionen

  • Department of Pathology, Johns Hopkins University School of Medicine, 1550 Orleans Street, CRB II 307, Baltimore, MD 21287, USA.
  • Department of Biochemistry and Molecular Biology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD 21287, USA.
  • Department of Cell Biology, Johns Hopkins University, Baltimore, MD 21287, USA.
  • Department of Obstetrics and Gynecology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
  • Department of Molecular Microbiology and Immunology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
  • Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.

ORCID-Profile: Yichu Xu, Chuan-Hsiang Huang

Förderung

  • NCI NIH HHS
  • NIH/NCI Specialized Program of Research Excellence (SPORE) in Cervical Cancer
  • NIDCR NIH HHS
  • NCI

Zitieren

APA

Xu, Y., Liu, Y., Chang, Y. C., Tsai, Y. C., Huang, C. H., Wu, T. C., & Hung, C. F. (2026). A Spike-Linked HPV16 E7 DNA Vaccine Induces Potent Antitumor and Anti-Spike Immune Responses. International Journal of Molecular Sciences, 27(14), 6249. https://doi.org/10.3390/ijms27146249

Vancouver

Xu Y, Liu Y, Chang YC, Tsai YC, Huang CH, Wu TC, et al. A Spike-Linked HPV16 E7 DNA Vaccine Induces Potent Antitumor and Anti-Spike Immune Responses. International Journal of Molecular Sciences. 2026;27(14):6249. doi:10.3390/ijms27146249

BibTeX
@article{Xu2026,
  author = {Xu, Yichu and Liu, Yining and Chang, Yu-Cheng and Tsai, Ya-Chea and Huang, Chuan-Hsiang and Wu, Tzyy-Choou and Hung, Chien-Fu},
  title = {A Spike-Linked HPV16 E7 DNA Vaccine Induces Potent Antitumor and Anti-Spike Immune Responses},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  volume = {27},
  number = {14},
  pages = {6249},
  doi = {10.3390/ijms27146249}
}
Kostenlos starten →